SCA
MRNA icon

Spearhead Capital Advisors’s Moderna MRNA Stock Holding History

Spearhead Capital Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,795
Closed -$256K – 135
2022
Q2 		$256K Sell
1,795
-480
-21% -$68.6K 0.04% 138
2022
Q1 		$392K Buy
2,275
+744
+49% +$125K 0.05% 105
2021
Q4 		$389K Buy
1,531
+5
+0.3% +$1.46K 0.05% 124
2021
Q3 		$587K Sell
1,526
-57
-4% -$21K 0.08% 84
2021
Q2 		$372K Sell
1,583
-2,771
-64% -$495K 0.05% 156
2021
Q1 		$570K Buy
4,354
+131
+3% +$19K 0.08% 77
2020
Q4 		$441K Sell
4,223
-671
-14% -$67.9K 0.07% 111
2020
Q3 		$346K Sell
4,894
-20
-0.4% -$1.39K 0.07% 112
2020
Q2 		$316K Sell
4,914
-3,948
-45% -$216K 0.07% 97
2020
Q1 		$265K Buy
+8,862
New +$204K 0.08% 88

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Spearhead Capital Advisors's MRNA Position: Q3 2022 in Review

Spearhead Capital Advisors sold out of Moderna (MRNA) in Q3 2022, closing a stake of 1,795 shares — an estimated $256K sold.

Spearhead Capital Advisors first reported a position in MRNA in Q1 2020 and held it in 10 quarters. The position peaked at $587K in Q3 2021. 916 funds tracked by Wall St. Rank hold MRNA as of Q3 2022.

  • Spearhead Capital Advisors reported no remaining Moderna position as of Q3 2022 after selling out during the quarter.
  • Spearhead Capital Advisors sold 1,795 Moderna shares in Q3 2022, an estimated $256K.
  • Spearhead Capital Advisors first reported a position in Moderna in Q1 2020 and held it in 10 quarters.
  • Spearhead Capital Advisors's Moderna position peaked at $587K in Q3 2021.
  • 916 funds tracked by Wall St. Rank held Moderna as of Q3 2022.

Based on Spearhead Capital Advisors's 13F filing for Q3 2022, filed 9 Nov 2022.